Friday, October 20, 2017 12:41:51 PM
Beginning with the roughly 33 that never received DCVax-L. The publication can tell us how many of those did not progress by let's say July 2017 (38 months after midterm enrollment). Perhaps 11 (10% of the 110 controls failed to progress and that would be extraordinary after a 38 months midpoint. Perhaps they can even tell you that 13 of those 33 controls are still alive (11 controls that have not progressed and 2 of the remaining very sick group of 22 controls that did not get the vaccine and did progress).
They may also be able to tell you that in addition to the 11 PFS in the 33 unvaccinated control group they had 60 PFS in the remaining 298 patients (the 90% who received DCVax-L early or late). That 71 PFS number would be down from the roughly 83 PFS that were reported on 2/6/17. I am assuming an attrition of about 2 PFS per months if the 248 PFS event occurred during 12/16 since I disagree with you that it could have occurred that much earlier.
Since we had 11 PFS of the 71 in the control group we would have 60 living PFS all belonging to the 220 trial group. Since we have a total of 71 PFS (60 trial and 11 control) about 27 living patients remain from the hypothetical 98 living patients expected during July 2017. These 27 living patients must originate from the 160 progressed trial patients (220-60) and the late 78 late vaccinated controls (111-33). This is a ratio of trial to control of about 2:1 and if we assume that late DCVax-L is as efficacious as early DCVax-L we can add 18 trial and 9 controls to the list of the living. In summary we would have a total of 20 control (11+9) and 78 Trial (60+18) living during July 2017.
This ratio of 4:1 would be predictive of success (IMHO).
I realize that the numbers here are fictitious but I believe I was very conservative in assuming that 20 controls of 11 were still alive in 7/17.
Anyway the publication hopefully will have the real numbers so we shall see. Best Regards.
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM